Senti Bio to Host Conference Call and Webcast to Discuss SENTI-202 Clinical Data Being Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 on Monday, April 28th at 8:30 AM ET
The call will be hosted by Timothy Lu, MD, PhD, Chief Executive Officer and Co-Founder, and Kanya Rajangam, MD, PhD, President, Head of R&D and Chief Medical Officer, of Senti Bio. Interested participants and investors may access the conference call by dialing (877) 524-8416 (domestic) or +1 (412) 902-1028 (international). The webcast will be accessible on the Events page under the Investors section of the Company's website (www.sentibio.com) and will be archived for 90 days following the live event.
About Senti BioSenti Bio is a clinical-stage biotechnology company developing a new generation of cell and gene therapies for patients living with incurable diseases. To achieve this, Senti Bio is leveraging a synthetic biology platform called Gene Circuits to create therapies with enhanced precision and control. These Gene Circuits are designed to precisely kill cancer cells, spare healthy cells, increase specificity to target cells, and/or control the expression of drugs even after administration. Senti Bio's wholly-owned pipeline is comprised of cell therapies engineered with Gene Circuits to target challenging liquid and solid tumor indications. Senti's Gene Circuits work in both NK and T cell therapies. Senti Bio's lead program SENTI-202, a first-in-class off-the-shelf Logic-Gated selective CD33 OR FLT3 NOT EMCN CAR NK cell therapy, is currently enrolling patients in a Phase I clinical trial. Additionally, Senti Bio has preclinically demonstrated the potential breadth of Gene Circuits in other cell and gene therapy modalities, diseases outside of oncology, and continues to advance these capabilities through partnerships.Forward-Looking StatementsThis press release contains certain statements that are not historical facts and are considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally are identified by the words 'believe,' 'could,' 'predict,' 'continue,' 'ongoing,' 'project,' 'expect,' 'anticipate,' 'estimate,' 'intend,' 'strategy,' 'future,' 'opportunity,' 'plan,' 'may,' 'should,' 'will,' 'would,' 'will be,' 'will continue,' 'will likely result,' 'forecast,' 'seek,' 'target' and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements are predictions, projections, and other statements about future events that are based on current expectations of Senti Bio's management and assumptions, whether or not identified in this document, and, as a result, are subject to risks and uncertainties. Forward-looking statements include, but are not limited to, statements regarding future events, including the success of our future clinical development and ability to create shareholder value. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by any investor as, a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Senti Bio. Many factors could cause actual future results to differ materially from the forward-looking statements in this document, including but not limited to: (i) changes in domestic and foreign business, market, financial, political and legal conditions, (ii) changes in the competitive and highly regulated industries in which Senti Bio operates, variations in operating performance across competitors, changes in laws and regulations affecting Senti Bio's business, (iii) the ability to implement business plans, forecasts and other expectations, (iv) the risk of downturns and a changing regulatory landscape in Senti Bio's highly competitive industry, (v) risks relating to the uncertainty of any projected financial information with respect to Senti Bio, (vi) risks related to uncertainty in the timing or results of Senti Bio's clinical trial initiation and the progress of clinical trials, patient enrollment, and GMP manufacturing activities, (vii) Senti Bio's dependence on fourth parties in connection with clinical trial startup, clinical studies, and GMP manufacturing activities, (viii) risks related to delays and other impacts from macroeconomic and geopolitical events, increasing rates of inflation and rising interest rates on business operations, (ix) risks related to the timing and utilization of Senti Bio's grant from CIRM and net proceeds of the PIPE financing, and (x) the success of any future research and development efforts by Senti Bio. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the 'Risk Factors' section of Senti Bio's most recent Quarterly Report on Form 10-Q, filed with the U.S. Securities and Exchange Commission ('SEC'), and other documents filed by Senti Bio from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements in this document. There may be additional risks that Senti Bio does not presently know, or that Senti Bio currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements in this document. Forward-looking statements speak only as of the date they are made. Senti Bio anticipates that subsequent events and developments may cause Senti Bio's assessments to change. Except as required by law, Senti Bio assumes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events, or otherwise.
Investor Contact:JTC Team, LLCJenene Thomas(908) 824-0775SNTI@jtcir.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
22 minutes ago
- Business Wire
Afya Limited Releases 2024 Sustainability Report
BELO HORIZONTE, Brazil--(BUSINESS WIRE)-- Afya Limited (Nasdaq: AFYA; B3: A2FY34) ('Afya' or the 'Company'), the leading medical education group and medical practice solutions provider in Brazil, announces the release of its 2024 Sustainability Report. The document, which presents Afya's trajectory throughout 2024, follows the Global Reporting Initiative (GRI) standards and is aligned with the Sustainable Development Goals (SDGs). It also reports specific indicators from the Sustainability Accounting Standards Board (SASB) and elements of the International Integrated Reporting Council (IIRC). The sustainability report contains some of the results of the fifth Greenhouse Gas (GHG) Emissions Inventory. Both of which have undergone individual audits by KPMG. The report is divided into two publications a narrative document and a technical annex in Excel format, which addresses all GRI and SASB indicators. Afya's 2024 Sustainability Report is available at: About Afya Limited (Nasdaq: AFYA, B3: A2FY34) Afya is a leading medical education group in Brazil based on the number of medical school seats, delivering an end-to-end physician-centric ecosystem that serves and empowers students and physicians to transform their ambitions into rewarding lifelong experiences from the moment they join us as medical students through their medical residency preparation, graduation program, continuing medical education activities and offering medical practice solutions to help doctors enhance their healthcare services through their whole career.
Hamilton Spectator
35 minutes ago
- Hamilton Spectator
Biogen to Highlight Scientific Progress Across Alzheimer's Disease at the Alzheimer's Association International Conference 2025
CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) today announced upcoming scientific presentations at the 2025 Alzheimer's Association International Conference (AAIC), taking place July 27-31 in Toronto, Canada. Data on LEQEMBI® (lecanemab) will include 48-month results from the Clarity AD open-label extension, real-world evidence, and new insights into a subcutaneous formulation for maintenance dosing. Presentations on tau will explore tau-targeted therapies and biomarkers, including baseline characteristics of participants from CELIA, a Phase 2 trial evaluating the efficacy, safety, and tolerability of BIIB080, an investigational antisense oligonucleotide (ASO) therapy that targets tau. 'At AAIC, we are sharing data that underscore our ongoing efforts to advance both how Alzheimer's is treated and how care is delivered, including 48-month findings from the LEQEMBI Clarity AD open-label extension and new insights into the potential of subcutaneous maintenance dosing for LEQEMBI. We are also excited to share baseline characteristics from CELIA, our Phase 2 study of BIIB080, an investigational ASO therapy targeting tau,' said Priya Singhal, M.D., M.P.H., Head of Development at Biogen. 'As we deepen our understanding of this complex disease, we remain committed to pushing the science forward and evolving care to better meet the needs of patients and families.' Key Scientific Sessions and Presentations: Educational Program on Tau in Alzheimer's Disease At AAIC, Biogen will host an interactive booth offering an immersive journey into the role of tau in Alzheimer's disease, from pathology to clinical presentation. Biogen is also expanding its educational efforts with a new e-learning module on , building on the resources already available. For more information, please see the AAIC 2025 program and visit the Biogen AAIC booth. About BIIB080 BIIB080 is an investigational antisense oligonucleotide (ASO) therapy designed to target microtubule-associated protein tau (MAPT) mRNA to reduce the production of tau protein. Abnormal accumulation of tau in the brain is a hallmark of Alzheimer's disease and is associated with neurodegeneration and cognitive decline. BIIB080 is currently being evaluated in a Phase 2 clinical study (NCT05399888) in individuals with early Alzheimer's disease. In December 2019, Biogen exercised a license option with Ionis Pharmaceuticals and obtained a worldwide, exclusive, royalty-bearing license to develop and commercialize BIIB080 (tau ASO). BIIB080 was discovered by Ionis. About LEQEMBI ® (lecanemab) LEQEMBI (lecanemab) is the result of a strategic research alliance between Eisai and BioArctic. LEQEMBI is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ). LEQEMBI is an amyloid beta-directed antibody for the treatment for Alzheimer's disease (AD) in the U.S. The U.S. Food and Drug Administration (FDA) granted LEQEMBI traditional approval on July 6, 2023. LEQEMBI is indicated for the treatment of Alzheimer's disease. Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials. Eisai and Biogen have been collaborating on the joint development and commercialization of AD treatments since 2014. Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with both companies co-commercializing and co-promoting the product and Eisai having final decision-making authority. Please see full U.S. Prescribing Information for LEQEMBI, including Boxed WARNING and Medication Guide . About Biogen Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients' lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth. We routinely post information that may be important to investors on our website at . Follow us on social media - Facebook , LinkedIn , X , YouTube . Biogen Safe Harbor This news release contains forward-looking statements, including about the potential clinical effects of lecanemab and BIIB080; the potential benefits, safety and efficacy of lecanemab and BIIB080; potential regulatory discussions, submissions and approvals and the timing thereof; the treatment of Alzheimer's disease; the anticipated risks, benefits and potential of Biogen's collaboration arrangements with Eisai; the potential of Biogen's commercial business and pipeline programs, including lecanemab and BIIB080; and risks and uncertainties associated with drug development and commercialization. These forward-looking statements may be accompanied by such words as 'aim,' 'anticipate,' 'assume,' 'believe,' 'contemplate,' 'continue,' 'could,' 'estimate,' 'expect,' 'forecast,' 'goal,' 'guidance,' 'hope,' 'intend,' 'may,' 'objective,' 'plan,' 'possible,' 'potential,' 'predict,' 'project,' 'prospect,' 'should,' 'target,' 'will,' 'would,' and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements. Given their forward-looking nature, these statements involve substantial risks and uncertainties that may be based on inaccurate assumptions and could cause actual results to differ materially from those reflected in such statements. These forward-looking statements are based on management's current beliefs and assumptions and on information currently available to management. Given their nature, we cannot assure that any outcome expressed in these forward-looking statements will be realized in whole or in part. We caution that these statements are subject to risks and uncertainties, many of which are outside of our control and could cause future events or results to be materially different from those stated or implied in this document, including, among others, uncertainty of long-term success in developing, licensing, or acquiring other product candidates or additional indications for existing products; expectations, plans and prospects relating to product approvals, approvals of additional indications for our existing products, sales, pricing, growth, reimbursement and launch of our marketed and pipeline products; our ability to effectively implement our corporate strategy; risks associated with third party collaborations; the risk that positive results in a clinical trial may not be replicated in subsequent or confirmatory trials or success in early stage clinical trials may not be predictive of results in later stage or large scale clinical trials or trials in other potential indications; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; the occurrence of adverse safety events, restrictions on use with our products, or product liability claims; risks of unexpected costs or delays or other unforeseen hurdles; and any other risks and uncertainties that are described in other reports we have filed with the U.S. Securities and Exchange Commission. These statements speak only as of the date of this press release and are based on information and estimates available to us at this time. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. Investors are cautioned not to put undue reliance on forward-looking statements. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and in our subsequent reports on Form 10-Q and Form 10-K, in each case including in the sections thereof captioned 'Note Regarding Forward-Looking Statements' and 'Item 1A. Risk Factors,' and in our subsequent reports on Form 8-K. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements whether as a result of any new information, future events, changed circumstances or otherwise.
Business Upturn
37 minutes ago
- Business Upturn
XRP breaks through resistance and price surges 90%, PBK Miner launches revolutionary XRP cloud mining, igniting the XRP market
By GlobeNewswire Published on July 22, 2025, 04:15 IST Los Angeles, California, July 21, 2025 (GLOBE NEWSWIRE) — XRP has had a great week, hitting an eye-popping $3.66 on Friday, a massive 90% increase from April levels. Now just a stone's throw away from XRP's legendary peak of $3.84 during the 2018 bull run, as enthusiasm in the cryptocurrency market soars, PBKMiner has officially launched a groundbreaking innovation: Ripple's XRP cloud mining contract – no hardware required, daily rewards, and fully remote access for users around the world. The upward trend continues as global financial institutions increasingly adopt Ripple's liquidity framework. As tokenized assets and stablecoins gradually become mainstream, XRP is more than just a cryptocurrency, it is gradually becoming the backbone of Ripple's plan to unlock more than $100 trillion in global liquidity. As a neutral digital bridge asset, XRP enables fast settlement between different currencies, assets and networks. 'The current XRP ecosystem has entered the fast lane. PBKMiner's goal is to help users seize this growth opportunity. Without hardware and maintenance, users can easily participate in mining and obtain daily income.' PBKMiner's operations director said, 'We see that short- and medium-term contracts are particularly popular among young users and novice investors because they have a low entry barrier, short cycle and fast returns.' XRP Cloud Mining Now Available—Easy, Smart, and ProfitableXRP has long been recognized for its role in cross-border payments and institutional financing, and now PBKMiner's latest innovation – user-friendly cloud mining, takes XRP to the next can mine XRP directly or take advantage of PBKMiner's intelligent AI engine, which automatically transfers mining power to the highest-yielding assets, including BTC, ETH, DOGE, USDC, and more. Earnings will be paid daily in the cryptocurrency of your choice, providing a reliable source of income regardless of market you are a novice or an experienced investor, with the PBKMiner AI cloud mining platform, you don't need to buy mining machines or professional skills, and everyone can easily participate in mining. In just three steps, you can start your journey of passive income from digital assets. Start earning income in just three easy steps: Register – Create an account and receive a $10 welcome bonus. Choose a plan – Select a short-term or long-term contract (1-55 days available). Start earning – Track your daily rewards and withdraw them in your preferred token. Why is PBKMiner's XRP mining so unique and leading?◆ XRP Integration: Activate mining contracts instantly with XRP.◆ Available to everyone: No technical skills, no hardware, no complex operations – just click to make money.◆ AI Intelligent Optimization: Artificial Intelligence mining strategies can bring stable returns in a variety of assets.◆ Built-in flexibility: Choose to mine XRP or diversify to other top cryptocurrencies – all with just one contract.◆ Global instant access: Start mining securely from anywhere in the world through a browser or app. ◆ Environmentally compliant operations: Mining operations use green energy and fully comply with UK and global standards Mining contract solutions to suit every budget and strategy:PBKMiner offers a variety of XRP-based cloud mining contracts designed for flexibility, predictable income, and effective risk management:$10 contract – 1 day – earn $0.6$100 contract – 2 days – earn $3.5 per day$500 contract – 5 days – earn $6.5 per day$5,000 contract – 30 days – earn $77.50 per day$30,000 contract – 50 days – earn $525.00 per dayWhether you are investing for the first time or building a long-term portfolio, PBKMiner offers transparent, low-risk contracts that bring a steady daily XRP data are not predictions, but real experiences of millions of users, thanks to PBKMiner's profit optimization based on artificial intelligence and result-centric mining model. Click here to explore all mining contracts. Key features of PBKMiner's XRP cloud mining contract:1. Focus on XRP ecosystem integration: Take advantage of XRP's fast settlement speed to seamlessly deposit, mine and withdraw XRP on the platform.2. Multi-currency mining support: Support earning XRP, BTC, ETH, DOGE, USDC, USDT, SOL, LTC and BCH, etc.3. AI-driven income optimization: Advanced proprietary algorithms optimize mining allocation to achieve maximum profitability and reduce costs.4. No hardware required: 100 remote access, cloud-based operations are fully accessible through the PBKMiner application or browser.5. Fund security protection: Daily automatic settlement, clear and traceable returns, all contracts return the full principal at maturity, minimize risks, and fully protect user assets. 6. Technology and service: An experienced team of experts and customer service staff are at your service 24/7. About PBKMiner As a leading digital asset management platform, since its establishment in 2019, PBKMiner has expanded its cloud mining business for XRP, BTC, ETH, LTC, DOGE and SOL in 183+ countries and regions, serving millions of active users around the world. Relying on a strong technical background and stable mining infrastructure, it makes cryptocurrency mining smarter, simpler and more inclusive, eliminating the technical barriers of traditional mining, and providing a transparent and low-risk stable mining income, especially for investors who seek sustainable long-term returns rather than speculative gains. For full details and participation options, please visit: Disclaimer: The information provided in this press release does not constitute an investment solicitation, nor does it constitute investment advice, financial advice, or a trading recommendation. Cryptocurrency mining and staking involve risks and may result in the loss of funds. It is strongly recommended that you perform due diligence before investing or trading in cryptocurrencies and securities, including consulting a professional financial advisor. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
